Debiopharm Group(TM) Moves Forward Three of Its Oncology Clinical Programs and Will Present the Recent Progresses at the 50th American Society of Clinical Oncology (ASCO) Annual Meeting

May 28, 2014

LAUSANNE, Switzerland, May 28, 2014 /PRNewswire/ –

Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical company
developing prescription drugs that target unmet medical needs as well as companion
diagnostics, today announced that new data on the investigational compounds Debio 1143
(SMAC mimetic), Debio 1347/CH5183284 (FGFR 1,2,3 inhibitor), and Debio 0932 (Hsp90
inhibitor) will be presented at the 50th American Society of Clinical Oncology (ASCO)
Annual Meeting, May 30 to June 3, 2014, in Chicago.

Debio 1143 is an orally available small molecule inhibitor of apoptosis proteins
(IAPs) that mimics the activity of the natural second mitochondrial-derived activator of
caspases (SMAC). By targeting IAPs, Debio 1143 can induce cancer cell death and potentiate
the efficacy of chemo- and/or radiotherapy. Debio 1143 has been assessed in two phase I
clinical studies and two phase I/II trials are ongoing in Europe.

Debio 1347/CH5183284 is a selective oral fibroblast growth factor receptor (FGFR) 1,
2, 3 inhibitor that has shown anti-cancer efficacy in several preclinical animal models in
vivo. Debio 1347/CH5183284 will enable personalized treatments and will be developed with
a companion diagnostic. Debio 1347/CH5183284 is currently being evaluated in Europe and
USA, in a first-in-man phase I trial in patients with advanced solid tumors displaying
alterations of the FGFR 1, 2, or 3 genes.

Debio 0932 is a small oral molecule inhibitor of heat shock protein 90 (HSP90).
Inhibition of HSP90 results in the degradation of oncoproteins that drive malignant
progression and leads to cell death. Debio 0932 has shown efficacy in various mouse tumor
xenografts and exhibits sustained tumor retention. Debio 0932 has been investigated in one
phase I clinical study. Two phase I/II studies are ongoing in Europe in advanced non-small
cell lung cancer (NSCLC) and renal cell carcinoma (RCC) in combination with SOC and
everolimus, respectively.

“We are very pleased to present results of our strong involvement in cancer treatment
research and further establish our commitment to this challenging medical field,” said
Jean-Maurice Dumont, Vice-President Medical Affairs. “The ability to relieve people with
cancer is an accomplishment.”

List of abstracts presented at ASCO:

                                                                              Abstract & Poster
        Compound   Description of study                                            number
        Debio 1143 First-in-human, pharmacokinetic (PK) and pharmacodynamics        #2532
                   (PD) phase I study of Debio 1143 (AT406) in patients with
                   advanced cancer. Final results.
                   Phase I study of Debio 1143 (AT406) in combination with          #7029
                   daunorubicin (D) and cytarabine (C) in patients with
                   poor-risk acute myeloid leukemia (AML).
                   A phase I/II randomized study of Debio 1143 combined with      #TPS6097
                   concurrent chemo-radiation therapy (CCRT) in patients with
                   locally advanced squamous cell carcinoma of the head and
                   neck (LA-SCCHN).
                   Clinical PK/PD model for Debio 1143, a novel antagonist of       #2585
                   IAPs in cancer treatment

        Debio 1347 First-in-human phase I "basket" study of Debio1347             #TPS2629
                   (CH5183284), a novel FGFR inhibitor, in patients with FGFR
                   genomically activated advanced solid tumors.

        Debio 0932 Final results from the phase I study expansion cohort of         #2550
                   Debio 0932, an oral HSP90 inhibitor, in patients with
                   solid tumors.
                   The HALO study: A phase I-II of the oral HSP90 inhibitor       #TPS2632
                   Debio 0932 in combination with SOC in first- and
                   second-line therapy of advanced NSCLC.

About Debiopharm Group(TM)

Debiopharm Group(TM) is a Swiss-based global biopharmaceutical group of four companies
active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and
investments. Debiopharm International SA is focused on the development of prescription
drugs that target unmet medical needs. The company in-licenses, develops and/or
co-develops promising biological and small molecule drug candidates for global
registration. The products are commercialized through out-licensing to pharmaceutical
partners to give access to the largest number of patients worldwide.

For more information about Debiopharm Group(TM), please visit:


        Debiopharm International SA Contact
        Christelle Tur
        Communication Coordinator
        Tel.: +41(0)21-321-01-11

        Additional Media Contacts
        In London
        Brian Hudspith
        Tel: +44(0)20-7379-5151

        In New York
        Russo Partners, LLC
        Martina Schwarzkopf, Ph.D.
        Account Executive
        Tel: +1-212-845-4292

SOURCE Debiopharm Group

Source: PR Newswire

comments powered by Disqus